2 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
Follow Prolymphocytic Leukemia: new trials by email Literature Review of Prolymphocytic Leukemia trials Research Report on Prolymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant Ibrutinib, Idelalisib - Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2016-03-01 | 2017-09-27 | |
| Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation sotrastaurin acetate, pharmacological study, laboratory biomarker analysis - Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma | Phase 2 | Withdrawn | James Blachly | 2015-03-12 | 2017-04-05 |
Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Prolymphocytic (2) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1)
Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, B-Cell (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Pathologic Processes (2)
ibrutinib (1) · idelalisib (1) · sotrastaurin (1)
Fred Hutchinson Cancer Center (1) · James Blachly (1)
United States (1)
James Blachly, MD (1) · Mohamed Sorror (1)
P01CA018029 (1), P30CA015704 (1)